Daiichi Sankyo submits sNDA for Omicron XBB.1.5-adapted COVID vaccine in Japan
Tokyo: Daiichi Sankyo has announced that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for an omicron XBB.1.5-adapted mRNA vaccine (DS-5670) against the novel coronavirus infectious disease (COVID-19) for booster vaccination for individuals aged 12 years or older.
The monovalent vaccine containing omicron XBB.1 lineage will be used in the current special temporary vaccination program against COVID-19 in Japan that begins in September 2023, and Daiichi Sankyo is advancing production preparations to start the supply of DS-5670 within this year.
Daiichi Sankyo has been developing the vaccine business in Japan in cooperation with Daiichi Sankyo Biotech Co., Ltd., a vaccine production functional subsidiary of the Daiichi Sankyo Group.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd